These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 29469177)

  • 61. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
    Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
    Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Intermittent inotropic therapy with levosimendan vs. milrinone in advanced heart failure patients.
    Milwidsky A; Frydman S; Laufer-Perl M; Sadeh B; Sapir O; Granot Y; Hochstadt A; Korotetski L; Ketchker L; Topilsky Y; Banai S; Havakuk O
    ESC Heart Fail; 2022 Apr; 9(2):1487-1491. PubMed ID: 35083882
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy.
    Pölzl G; Altenberger J; Baholli L; Beltrán P; Borbély A; Comin-Colet J; Delgado JF; Fedele F; Fontana A; Fruhwald F; Giamouzis G; Giannakoulas G; Garcia-González MJ; Gustafsson F; Kaikkonen K; Kivikko M; Kubica J; von Lewinski D; Löfman I; Malfatto G; Manito N; Martínez-Sellés M; Masip J; Merkely B; Morandi F; Mølgaard H; Oliva F; Pantev E; Papp Z; Perna GP; Pfister R; Piazza V; Bover R; Rangel-Sousa D; Recio-Mayoral A; Reinecke A; Rieth A; Sarapohja T; Schmidt G; Seidel M; Störk S; Vrtovec B; Wikström G; Yerly P; Pollesello P
    Int J Cardiol; 2017 Sep; 243():389-395. PubMed ID: 28571618
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysis.
    Silvetti S; Nieminen MS
    Int J Cardiol; 2016 Jan; 202():138-43. PubMed ID: 26386941
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Use of levosimendan combined with Shenfu injection to treat acute heart failure patients with hypotension: a prospective randomized controlled single-blind study.
    Li M; Zhang Y; Wan Q; Li Y; Qu T; Yuan F
    BMC Cardiovasc Disord; 2022 Mar; 22(1):130. PubMed ID: 35350988
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure.
    Yilmaz MB; Yontar C; Erdem A; Karadas F; Yalta K; Turgut OO; Yilmaz A; Tandogan I
    Heart Vessels; 2009 Jan; 24(1):16-21. PubMed ID: 19165563
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Levosimendan in outpatients with advanced heart failure: Single-center experience of 200 intermittent perfusions.
    Ferreira Reis J; Valentim Gonçalves A; Ilhão Moreira R; Pereira da Silva T; Timóteo AT; Pombo D; Carvalho T; Correia C; Santos C; Cruz Ferreira R
    Rev Port Cardiol; 2023 Apr; 42(4):335-343. PubMed ID: 36634758
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Value of IGF-I levels in the evaluation of response to treatment with levosimendan in patients with severe heart failure.
    Işık S; Cetin M; Ciçekçioğlu H; Uçar O; Çetin ZG; Ozuğuz U; Bakır F; Berker D; Güler S
    Anadolu Kardiyol Derg; 2011 Sep; 11(6):523-9. PubMed ID: 21821501
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Therapy of acute decompensated heart failure with levosimendan].
    Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
    Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
    Labriola C; Siro-Brigiani M; Carrata F; Santangelo E; Amantea B
    Int J Clin Pharmacol Ther; 2004 Apr; 42(4):204-11. PubMed ID: 15124978
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Economic analysis of intermittent intravenous outpatient treatment with levosimendan in advanced heart failure in Spain.
    Manito Lorite N; Rubio-Rodríguez D; González Costello J; Díez López C; Enjuanes Grau C; Segovia-Cubero J; Delgado Jimenez JF; Campo Sien C; Rubio-Terrés C; Comín-Colet J; ;
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):361-367. PubMed ID: 31899185
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry.
    Dobarro D; Donoso-Trenado V; Solé-González E; Moliner-Abós C; Garcia-Pinilla JM; Lopez-Fernandez S; Ruiz-Bustillo S; Diez-Lopez C; Castrodeza J; Méndez-Fernández AB; Vaqueriza-Cubillo D; Cobo-Marcos M; Tobar J; Sagasti-Aboitiz I; Rodriguez M; Escolar V; Abecia A; Codina P; Gómez-Otero I; Pastor F; Marzoa-Rivas R; González-Babarro E; de Juan-Baguda J; Melendo-Viu M; de Frutos F; Gonzalez-Costello J
    ESC Heart Fail; 2023 Apr; 10(2):1193-1204. PubMed ID: 36655614
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ambulatory levosimendan infusions. Effective and efficient in advanced heart failure?
    Dobarro D; Ribera-Solé A
    Rev Esp Cardiol (Engl Ed); 2020 May; 73(5):345-347. PubMed ID: 32107145
    [No Abstract]   [Full Text] [Related]  

  • 77. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Levosimendan improves cardiac function and survival in rats with angiotensin II-induced hypertensive heart failure.
    Biala A; Martonen E; Kaheinen P; Levijoki J; Finckenberg P; Merasto S; Louhelainen M; Muller DN; Luft FC; Mervaala E
    Hypertens Res; 2010 Oct; 33(10):1004-11. PubMed ID: 20811386
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Hemodynamic Effects and Safety of Repetitive Levosimendan Infusions on Children With Dilated Cardiomyopathy.
    Suominen P; Mattila N; Nyblom O; Rautiainen P; Turanlahti M; Rahkonen O
    World J Pediatr Congenit Heart Surg; 2017 Jan; 8(1):25-31. PubMed ID: 28033083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.